Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20503161 | 1.00 | DUT (0.52) | DUTP2RY14P2RY6SLC28A1SLC28A2 | |
| SCHEMBL26373405 | 0.91 | DUT (0.56) | DUTP2RY14P2RY6SLC28A1SLC28A2 | |
| SCHEMBL26133860 | 0.91 | DUT (0.56) | DUTP2RY14P2RY6SLC28A1SLC28A2 | |
| SCHEMBL10391187 | 0.91 | DUT (0.56) | DUTP2RY14P2RY6SLC28A1SLC28A2 | |
| SCHEMBL24781265 | 0.91 | DUT (0.56) | DUTP2RY14P2RY6SLC28A1SLC28A2 | |
| SCHEMBL24782135 | 0.91 | DUT (0.56) | DUTP2RY14P2RY6SLC28A1SLC28A2 | |
| SCHEMBL26373418 | 0.91 | DUT (0.56) | DUTP2RY14P2RY6SLC28A1SLC28A2 | |
| SCHEMBL6760952 | 0.91 | DUT (0.56) | DUTP2RY14P2RY6SLC28A1SLC28A2 | |
| SCHEMBL780746 | 0.88 | DUT (0.56) | DUTP2RY14P2RY6SLC28A1SLC28A2 | |
| SCHEMBL780745 | 0.88 | DUT (0.56) | DUTP2RY14P2RY6SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | NISSAN CHEMICAL CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
| EP-3378869-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Nissan Chemical Corporation (JP) | 2018-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | DUT 13/4885P2RY14 1608/4885P2RY6 1099/4885 |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, OSGEP, PHAX | DUT 13/4885P2RY14 1608/4885P2RY6 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.